PMID: 11316020Apr 24, 2001Paper

Management of corneal epithelial defects following laser in situ keratomileusis

Journal of Refractive Surgery
E SmirennaiaO Kashnikova

Abstract

To determine the main principles of postoperative management in patients with epithelial defects following LASIK. Patients with myopia and myopic astigmatism (N=2,972; refraction from -1.25 to -15.50 D) were treated with the Nidek EC-5000 excimer laser, using the Chiron Vision HT-230 Hansatome microkeratome. We observed 95 cases with intraoperative epithelial damage among 5,896 operations (1.6%) . Patients received traditional topical medical treatment (Tobramycin 0.3%, five times a day; Lacrisifi, six to eight times a day). In eyes with an epithelial defect less then 3 mm, no additional medical care was needed. In eyes with epithelial defects more then 3 mm, soft therapeutic contact lenses were used until total re-epithelialization occurred. Total re-epithelialization was observed the day following surgery in patients with small defects (less then 3 mm). Visual acuity achieved preoperative level 4 to 7 days after surgery. Total re-epithelialization in patients with soft contact lenses occurred 1 to 3 days after LASIK. On the next day examination, Solcoseryl 20% eye gel was added to topical therapy for corneal healing. In these patients visual acuity achieved preoperative level 10 to 14 days after surgery. In three eyes with la...Continue Reading

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.